When we talk about the CannaInvestor Advantage, this NYSE listed company is #111 on the 2017 Fortune 500 list and I truly cannot find any other industry publication that discussed ABBV prior to CannaInvestor Magazine.
ABBV itself is not a true cannabis focused company; however, the company already has one cannabis-based drug, called Marinol that is approved by the FDA. This June 2017 publication provides an excellent background of ABBV and its drug Marinol. The drug is typically prescribed for cancer patients and those with HIV who have lost their appetites.
According to some sources, ABBV is the 8th largest Pharma company in the world. They are a serious force and given their existing drug Marinol it would not be too much of a stretch to see ABBV expand aggressively into the legal hemp and cannabis industry once it is politically and legally stable to do so.
Scott’s Miracle-Gro Company
NYSE:SMG
As At Date 11/24/2017
Shares Outstanding: 158,411,264 (www.investing.com)
Share Price: $0 Market Cap: $0
Qtr. Dividend: $0.53
It was in July 2016 that SMG became known for its presence in the cannabis industry but its actual entry was a few years before. Ancillary of course selling fertilizers, soils and accessories.
Fast forward to May 2017 when SMG announced it wanted a larger presence in the industry in those States where marijuana was legal through its wholly owned subsidiary Hawthorne Gardening Co.
And in August, SMG made an announcement that was stunning to some – it was selling off its international operations to focus on core business and hydroponics. In this same announcement, SMG announced a pending acquisition of a "marquee brand" in hydroponics. According to that article (click the words “pending acquisition”), “. . . allows Scotts to dedicate its money and attention to its long-established core business and its high-flying venture into hydroponics. Scotts has spent hundreds of millions of dollars plucking up sector leaders and folding them into subsidiary Hawthorne Gardening Co. in a move to capitalize on the ancillary wings of the fledgling U.S. marijuana industry”.
73